Clinical Evaluation of a Small Aperture Extended Depth of Focus Intraocular Lens
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- AcuFocus, Inc.
- Enrollment
- 453
- Locations
- 42
- Primary Endpoint
- Mean Monocular Best-corrected Distance (4 m) Visual Acuity (BCDVA)
Study Overview
Brief Summary
The purpose of this study is to determine the safety and effectiveness of the IC-8 IOL implanted in one eye and a monofocal or monofocal toric IOL implanted in the fellow eye in accordance with the indication.
Detailed Description
Eligible patients will complete up to 12 study visits over a 12-month period. All subjects will complete a preoperative examination of both eyes to assess study eligibility: operative visit (each eye) and up to 9 postoperative visits (Day 1 - each eye, Week 1 - each eye, Month 1 - each eye or combined, Month 3 - both eyes, Month 6 - both eyes, and Month 12 - both eyes). The first eye must meet specific qualification criteria in order to proceed with IOL implantation in the second eye. The second eye should be implanted within 45 days of the first eye.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
Masking Description
Examiner masked
Eligibility Criteria
- Ages
- 22 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Minimum 22 years of age;
- •Able to comprehend and have signed a statement of informed consent;
- •Availability, willingness, ability and sufficient cognitive awareness to comply with examination procedures and study visits;
- •Planned crystalline lens removal by phacoemulsification, with or without femtosecond laser-assisted extraction, and posterior chamber IOL implantation in both eyes;
- •Cataractous lens changes as demonstrated by best-corrected visual acuity (BCDVA) of 20/40 or worse either with or without a glare source present;
- •Potential for postoperative BCDVA of 20/25 or better in each eye
- •Clear intraocular media, other than cataract.
Exclusion Criteria
- •Requiring an IC-8 intraocular lens outside the available spherical power range
- •Pharmacologically dilated pupil size less than 6 mm in either eye;
- •Inability to achieve stable keratometric readings for contact lens wearers
- •Irregular astigmatism in either eye;
- •Preoperative corneal astigmatism > 1.50 diopters in either eye
- •Active or recurrent anterior segment pathology
- •Presence of ocular abnormalities other than cataract as specified in the protocol
- •Diagnosis of dry eye in which patients are unable to maintain eye comfort or adequate vision even with dry eye medication;
- •Congenital cataracts;
- •Previous corneal or intraocular surgery
- •History of ocular trauma or ocular conditions expected to require retinal laser treatment or other surgical intervention;
- •Systemic conditions as specified in the protocol;
- •Patient is pregnant, plans to become pregnant, or is lactating
- •Concurrent participation or participation in any clinical trial up to 30 days prior to preoperative visit.
Outcomes
Primary Outcomes
Mean Monocular Best-corrected Distance (4 m) Visual Acuity (BCDVA)
Time Frame: 12 Months (300-420 days post second eye operative visit)
Visual acuity (VA) was tested monocularly (each eye) at a distance of 4 m, in photopic conditions, with manifest refraction in place (no infinity adjustment) using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart presenting on a self-calibrating monitor in a computerized testing system. Visual acuity was measured in logarithm of the minimum angle of resolution (logMAR), with a 0.02 logMAR increment corresponding to a single letter on the ETDRS chart.
Mean Binocular Photopic Uncorrected Intermediate (66 cm) Visual Acuity (UCIVA)
Time Frame: 6 Months (160-210 days post second eye operative visit)
Visual acuity (VA) was tested binocularly (both eyes) at a distance of 66 cm, without manifest refraction, using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart presenting on a self-calibrating monitor in a computerized testing system. Visual acuity was measured in logarithm of the minimum angle of resolution (logMAR), with a 0.02 logMAR increment corresponding to a single letter on the ETDRS chart.
Mean Monocular Photopic Depth of Focus (DOF) in IC-8™ IOL Eyes
Time Frame: 3 Months (60-110 days post second eye operative visit)
Depth of focus was performed monocularly in the IC-8™ IOL Group at the far to near range of vision (+2.00 to -5.00 D), using 100% contrast ETDRS charts in a computerized testing system calibrated for a 4 m test distance, with manifest refraction (no infinity adjustment) in place for the eye(s) being tested. The defocus power was progressively introduced in 0.50 D increments from +2.00 D to +0.50 D and from -0.50 D to -5.00 D, then in 0.25 D increments from +0.50 D to -0.50 D, while visual acuity was measured at each successive defocus step. The depth of focus was estimated as the defocus range between zero defocus and the first point on the negative lens induced mean defocus curve that crosses the 0.2 logMAR using a linear interpolation.
Rates of IC-8™ IOL Eyes With Cumulative Ocular Serious Adverse Events
Time Frame: Through 12 Months (300-420 days post second eye operative visit)
The rates of cumulative ocular serious adverse events (SAEs) for IC-8™ IOL eyes were calculated from the time of second eye (IC-8™ IOL eye) implantation through Month 12.
Mean Binocular Photopic Uncorrected Near (40 cm) Visual Acuity (UCNVA)
Time Frame: 6 Months (160-210 days post second eye operative visit)
Visual acuity (VA) was tested binocularly (both eyes) at a distance of 40 cm, without manifest refraction, using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart presenting on a self-calibrating monitor in a computerized testing system. Visual acuity was measured in logarithm of the minimum angle of resolution (logMAR), with a 0.02 logMAR increment corresponding to a single letter on the ETDRS chart.
Mean Binocular Photopic Uncorrected Distance (4 m) Visual Acuity (UCDVA)
Time Frame: 6 Months (160-210 days post second eye operative visit)
Visual acuity (VA) was tested binocularly (both eyes) at a distance of 4 m, with +0.25 D infinity adjustment lens in front of the eyes, using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart presenting on a self-calibrating monitor in a computerized testing system. Visual acuity was measured in logarithm of the minimum angle of resolution (logMAR), with a 0.02 logMAR increment corresponding to a single letter on the ETDRS chart.
Rates of IC-8™ IOL Eyes With IC-8™ IOL Removals
Time Frame: Through 12 Months (300-420 days post second eye operative visit)
The rates of cumulative ocular adverse events for IC-8™ IOL eyes were calculated from the time of second eye (IC-8™ IOL eye) implantation through Month 12.
Rates of Eyes With Postoperative Ocular Adverse Events (Other Than Secondary Surgical Intervention), Related to Device (Serious and Non-Serious Combined)
Time Frame: Through 12 Months (300-420 days post second eye operative visit)
The rates of cumulative ocular adverse events (AEs) for IC-8™ IOL eyes were calculated from the time of second eye (IC-8™ IOL eye) implantation through Month 12.
Mean Monocular Photopic Distance-Corrected Intermediate (66 cm) Visual Acuity (DCIVA) in IC-8™ IOL Eyes
Time Frame: 6 Months (160-210 days post second eye operative visit)
Visual acuity (VA) was tested monocularly (each eye) at a distance of 66 cm, with the distance manifest refraction (with infinity adjustment) in place for that eye, using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart presenting on a self-calibrating monitor in a computerized testing system. Visual acuity was measured in logarithm of the minimum angle of resolution (logMAR), with a 0.02 logMAR increment corresponding to a single letter on the ETDRS chart.
Proportion of IC-8™ IOL Eyes Achieving Best-corrected Distance Visual Acuity (BCDVA) 0.3 logMAR or Better Compared to the Safety and Performance Endpoints (SPE) Rates
Time Frame: 12 Months (300-420 days post second eye operative visit)
Visual acuity (VA) was tested monocularly (each eye) at a distance of 4 m, in photopic conditions, with manifest refraction in place (no infinity adjustment) using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart presenting on a self-calibrating monitor in a computerized testing system. Visual acuity was measured in logarithm of the minimum angle of resolution (logMAR), with a 0.02 logMAR increment corresponding to a single letter on the ETDRS chart.
Proportion of Best-Case IC-8™ IOL Eyes Achieving Best-corrected Distance Visual Acuity (BCDVA) 0.3 logMAR or Better Compared to the Safety and Performance Endpoints (SPE) Rates
Time Frame: 12 Months (300-420 days post second eye operative visit)
Visual acuity (VA) was tested monocularly (each eye) at a distance of 4 m, in photopic conditions, with manifest refraction in place (no infinity adjustment) using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart presenting on a self-calibrating monitor in a computerized testing system. Visual acuity was measured in logarithm of the minimum angle of resolution (logMAR), with a 0.02 logMAR increment corresponding to a single letter on the ETDRS chart. Monocular BCDVA for the IC-8™ IOL eyes of subjects in the Best-Case population was compared to the safety and performance endpoints (SPE) rate for posterior chamber IOLs.
Rates of IC-8™ IOL Eyes With Cumulative Postoperative Ocular Adverse Events (Secondary Surgical Interventions)
Time Frame: Through 12 Months (300-420 days post second eye operative visit)
The rates of cumulative ocular adverse events for IC-8™ IOL eyes were calculated from the time of second eye (IC-8™ IOL eye) implantation through Month 12.
Rates of IC-8™ IOL Eyes With Persistent Ocular Serious Adverse Events
Time Frame: Through 12 Months (300-420 days post second eye operative visit)
The rates of persistent (defined as being unresolved at final scheduled visit) ocular adverse events (AEs) for IC-8™ IOL eyes were calculated from the time of second eye (IC-8™ IOL eye) implantation through Month 12.
Secondary Outcomes
- Mean Monocular Photopic Contrast Sensitivity With Glare(6 Months (160-210 days post second eye operative visit))
- Mean Binocular Photopic Contrast Sensitivity With Glare(6 Months (160-210 days post second eye operative visit))
- Mean Binocular Photopic Contrast Sensitivity Without Glare(6 Months (160-210 days post second eye operative visit))
- Tolerance to Preoperative Corneal Astigmatism in IC-8™ IOL Eyes With BCDVA 20/25 at 3 Months(3 Months (60-110 days post second eye operative visit))
- Mean Monocular Photopic Contrast Sensitivity Without Glare(6 Months (160-210 days post second eye operative visit))
- Mean Monocular Mesopic Contrast Sensitivity Without Glare(6 Months (160-210 days post second eye operative visit))
- Mean Monocular Mesopic Contrast Sensitivity With Glare(6 Months (160-210 days post second eye operative visit))
- Mean Binocular Mesopic Contrast Sensitivity Without Glare(6 Months (160-210 days post second eye operative visit))
- Mean Binocular Mesopic Contrast Sensitivity With Glare(6 Months (160-210 days post second eye operative visit))